You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. ARCUS BIOSCIENCES INC

Arcus Biosciences Inc XNYS: RCUS

Arcus Biosciences Inc Live Share Price Today, Share Analysis and Chart

Weak Stock
Download real time

7.85 -0.32 (-3.92%)

New 52W Low today

1.2M XNYS Volume

XNYS 31 Mar, 2025 4:00 PM (EDT)

Watchlist

Portfolio

Share

Arcus Biosciences Inc Key Metrics

Default

Market Capitalization

Below industry Median
830.9

PE TTM

Negative PE TTM
-2.9

PEG TTM

Negative PEG TTM
-0.4

Price to Book

Below industry Median
1.7

Institutional holding current Qtr %

Below industry Median
54.3

Revenue Growth Qtr YoY %

Negative Revenue Growth Qtr YoY %
-16.1

Operating Revenue growth TTM %

High in industry
120.5

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-16

Net Profit TTM Growth %

Below industry Median
7.8

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-396.2

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-120.2

Piotroski Score

Below industry Median
1

Rel Perf vs Sector quarter%

-54.4

ROE Annual %

Negative ROE Annual %
-59.8

RoA Annual %

Negative RoA Annual %
-25.2
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Low Financial Strength
11.1 / 100
Valuation Score
Expensive Valuation
18.2 / 100
Momentum Score
Technically Bearish
29.8 / 100
Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM
Analyst Price Target
33
1Yr Price target upside is 315%
11 analysts

7

S

27

W

0

O

3

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Arcus Biosciences Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '260200400Actual RevenueAvg. Estimate
Hit

Arcus Biosciences Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

Current EPS
-3.1
Avg. Estimate
-4.1
Low Estimate
-5.8
High Estimate
-3.3
Current EPS
Avg. Estimate
Miss

EPS is expected to reduce by 31.5% in FY25

Consensus Recommendation

13 ANALYST Recommendations
BUY

Created with Highcharts 7.2.22Hold3Buy8Strong Buy

The consensus recommendation from 13 analysts for Arcus Biosciences Inc is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Arcus Biosciences Inc Stock Analysis

Arcus Biosciences Inc stock analysis with key metrics, changes, and trends.

Arcus Biosciences Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$258 M120.51%positive

Annual Revenue rose 120.51%, in the last year to $258 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

Annual Net Profit$283 M7.82%positive

Annual Net Profit rose 7.82% in the last year to $283 M. Its sector's average net profit growth for the last fiscal year was -32.42%.

Price to Earning Ratio-2.94-negative

Price to Earning Ratio is -2.94, which is negative.

Stock Price$7.85-58.42%negative

Stock Price fell 58.42% and underperformed its sector by 64.88% in the past year.

Quarterly Revenue$26 M16.13%negative

Quarterly Revenue fell 16.13% YoY to $26 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit$94 M16.05%negative

Quarterly Net profit fell 16.05% YoY to $94 M. Its sector's average net profit growth YoY for the quarter was -47.39%.

Debt to Equity Ratio0.12-positive

Debt to Equity Ratio of 0.12 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-59.77 %-59.77%negative

Return on Equity(ROE) for the last financial year was -59.77%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding35.97 %-1.99%negative

Mutual Fund Holding decreased by 1.99% in the last quarter to 35.97.

Promoter Share Holding8.10 %-2.81%negative

Promoter Share Holding decreased by 2.81% in the most recent quarter to 8.1%.

Interest Coverage Ratio-69.75-negative

Interest Coverage Ratio is -69.75, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding54.34 %-5.67%negative

Institutional Holding decreased by 5.67% in the last quarter to 54.34.

VIEW LESS


Loading data..

Arcus Biosciences Inc - Company Profile

What does Arcus Biosciences Inc do?

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Arcus Biosciences Inc Management structure

All Gross Remunerations are in USD
Mr. Dimitry SA Nuyten, M.D.,PhD
Chief Medical Officer
-
2025
Gross Remuneration
Year
Dr. Richard Markus, M.D.
Chief Medical Officer
-
2025
Gross Remuneration
Year

Arcus Biosciences Inc Board of directors

All Gross Remunerations are in USD
Dr. Dietmar Berger, M.D.,PhD
Director
-
2025
Gross Remuneration
Year
Dr. Merdad V. Parsey, M.D.,PhD
Director
-
2025
Gross Remuneration
Year

Arcus Biosciences Inc FAQ

How is Arcus Biosciences Inc today?
Arcus Biosciences Inc today is trading in the red, and is down by -3.92% at 7.85.
Arcus Biosciences Inc is currently trading down -3.92% on an intraday basis. In the past week the stock fell -12.19%. stock has been down -47.35% in the past quarter and fell -58.42% in the past year. You can view this in the overview section.